Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

doi:10.1056/NEJMoa1503153

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.

The New England journal of medicine - 20 Aug 2015

Wyles David L, Ruane Peter J, Sulkowski Mark S, Dieterich Douglas, Luetkemeyer Anne, Morgan Timothy R, Sherman Kenneth E, Dretler Robin, Fishbein Dawn, Gathe Joseph C, Henn Sarah, Hinestrosa Federico, Huynh Charles, McDonald Cheryl, Mills Anthony, Overton Edgar Turner, Ramgopal Moti, Rashbaum Bruce, Ray Graham, Scarsella Anthony, Yozviak Joseph, McPhee Fiona, Liu Zhaohui, Hughes Eric, Yin Philip D, Noviello Stephanie, Ackerman Peter

Abstract excerpt

BACKGROUND: The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on the efficacy and safety of this combination in patients coinfected with human immunodeficiency virus type 1 (HIV-1). METHODS: This was an open-label study involving 151 patients who had not received HCV treatment and 52...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Retroviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbamates

Share to Drug Therapy, Combination

Share to Imidazoles

Share to Pyrrolidines

Share to Sofosbuvir

Share to Uridine Monophosphate

Share to Valine

Source

Open in PubMed

Identifiers

PMID: 26196502
DOI: 10.1056/NEJMoa1503153

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.PMID 26196502Read ↗

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.Semantic proximity Read ↗

Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.Semantic proximity Read ↗

Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.Semantic proximity Read ↗

Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.Semantic proximity Read ↗

Ledipasvir-Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection.Semantic proximity Read ↗

Ledipasvir-sofosbuvir for 6 weeks to treat acute hepatitis C virus genotype 1 or 4 infection in patients with HIV coinfection: an open-label, single-arm trial.Semantic proximity Read ↗

Sofosbuvir in combination with daclatasvir or simeprevir for 12 weeks in noncirrhotic subjects chronically infected with hepatitis C virus genotype 1: a randomized clinical trial.Semantic proximity Read ↗

Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.Semantic proximity Read ↗

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.Semantic proximity Read ↗

Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting.Semantic proximity Read ↗

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.Semantic proximity Read ↗

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.